Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 4/20 | 0.65 |
| ▸ | MMP2 | P08253 | 4/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670493 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL2328122 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL489156 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1267438 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1267008 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL25181712 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL1545946 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| SCHEMBL7729511 | 1.00 | ANPEP (0.65) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL1412084 | 0.98 | ANPEP (0.63) | ANPEPMMP2CYP1A2POLBCYP3A4 | |
| Hydrochloric Acid SCHEMBL2347422 | 0.98 | ANPEP (0.63) | ANPEPMMP2CYP1A2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119395192-B | Method for measuring isomers in carfilzomib and preparation thereof by reversed phase liquid chromatography | 合肥亿帆生物制药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119395192-A | Method for measuring isomers in carfilzomib and preparation thereof by reversed phase liquid chromatography | 合肥亿帆生物制药有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| EP-4426695-A1 | KRAS G12C INHIBITORS | Frontier Medicines Corporation (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-116888110-A | Melanocortin-4 receptor agonists | 株式会社LG 化学 | 2023-10-13 | — | — | CN | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2008148689-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| WO-2008077555-A2 | SUBSTITUTED ISOQUINOLINES AND THEIR USE AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | MORIARTY KEVIN J | 2005-10-27 | — | — | US | disclosed |
| US-6906067-B2 | N-heterocyclic inhibitors of TNF-α expression | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2005011697-A2 | SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | PHARMACEOPEIA, INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | PHARMACOPEIA, INC. | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239770-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, RELA, NFKBIA | ANPEP 1212/4885MMP2 1074/4885CYP1A2 403/4885 |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | ANPEP 1608/4885MMP2 3660/4885CYP1A2 137/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | ANPEP 4289/4885MMP2 4616/4885CYP1A2 2532/4885 |
| US-20020137747-A1 | N- heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | ANPEP 1460/4885MMP2 1120/4885CYP1A2 315/4885 |
| US-20020065270-A1 | N-heterocyclic inhibitors of TNF-alpha expression | TNF, NFKBIA, RELA | ANPEP 1460/4885MMP2 1120/4885CYP1A2 315/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | ANPEP 4001/4885MMP2 2455/4885CYP1A2 4759/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ANPEP 4001/4885MMP2 2455/4885CYP1A2 4759/4885 |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | SLC6A3, OPRL1, OPRK1 | ANPEP 271/4885MMP2 3631/4885CYP1A2 1733/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ANPEP 4001/4885MMP2 2455/4885CYP1A2 4759/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | ANPEP 1431/4885MMP2 2027/4885CYP1A2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.